Avastin Syringes Recalled for Sterility Concerns and Eye Infection Reports
Clinical Specialties Compounding Pharmacy is recalling Avastin syringes due to sterility assurance issues and reports of eye infections.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves reported adverse events of endophthalmitis (eye infections), which aligns with the rubric criterion for 'FDA Class II with hospitalization reports' or significant injury reports.
Plain-English summary
Clinical Specialties Compounding Pharmacy is recalling 2,190 single-unit dose syringes of Avastin (0.05 ml, 1.25 mg/0.05ml). The recall was initiated due to a lack of assurance of sterility and FDA inspection findings that raised concerns regarding the pharmacy's quality control processes.
The affected product is linked to adverse event reports of endophthalmitis, a type of eye infection. The recall covers specific lots distributed to facilities in Florida, Georgia, Indiana, Louisiana, and South Carolina.
Consumers and healthcare providers should stop using the affected syringes and contact the recalling firm for further instructions or a refund. The FDA has classified this as a Class II recall, indicating a reasonable probability that use of the product may cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- Avastin, (0.05 ml, 1.25 mg/0.05ml), single unit dose syringes, Clinical Specialties Compounding Pharmacy, Augusta, GA
- Manufacturer
- Clinical Specialties Compounding Pharmacy
- Category
- Drug — Ophthalmic
- Hazard
- Affected units
- 2,190
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #CABDAHAC:39
- Exp. Date: 5/8/2013
- Lot #CABDAGAC:58
- Exp. Date: 4/13/2013
- Lot #CABDAHAC:77
- Exp. Date: 4/8/2013
- Lot #CABDBIAC:86
- Exp. Date: 4/19/2013
- Lot #CABDCFAC:29
- Exp. Date: 4/26/2013
- Lot #CABDAEAD:26
- Exp. Date: 5/3/2013
- Lot #CABDAEAC:47
- Exp. Date: 5/5/2013
- Lot #CABDAEAC:58
- Lot #CABDAFAC:46
- Exp. Date: 5/6/2013
- Lot #CABDAIAC:46
- Exp. Date: 5/9/2013
- Lot #CABDBCAC:94
Distribution
Related recalls
Same manufacturer · Clinical Specialties Compounding Pharmacy
See all →- SevereClinical Specialties Compounding Pharmacy Recalls Methionine/Choline/Inositol/B-12 Injection
FDA (Drugs) · 2013-07-10
- SevereClinical Specialties Compounding Pharmacy Recalls Test Cyp 250 mg-lidocaine 5 mg/ml
FDA (Drugs) · 2013-07-10
- SevereEstradiol Cypionate Injection Recalled Due to Sterility Concerns
FDA (Drugs) · 2013-07-10
- SevereClinical Specialties Compounding Pharmacy Recalls Test Cyp 200 mg/ml Due to Sterility Concerns
FDA (Drugs) · 2013-07-10
- SevereClinical Specialties Compounding Pharmacy Recalls Test Cyp 100 mg/ml Due to Sterility Concerns
FDA (Drugs) · 2013-07-10
Same hazard · sterility
See all →- SevereRegeneron Recalls Libtayo Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-08-26
- SeverePrestige Recalls Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns
FDA (Drugs) · 2026-08-19
- SevereROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SevereFDA Recalls ROHTO OPTIC GLOW Eye Drops Over Sterility Concerns
FDA (Drugs) · 2026-07-29